Literature DB >> 18837683

Management of bronchiectasis and chronic suppurative lung disease in indigenous children and adults from rural and remote Australian communities.

Anne B Chang1, Keith Grimwood, Graeme Maguire, Paul T King, Peter S Morris, Paul J Torzillo.   

Abstract

1) Consensus recommendations for managing bronchiectasis in Indigenous children and adults living in rural and remote regions were developed during a multidisciplinary workshop and were based on available systematic reviews. 2) Successful diagnosis, management and prevention of bronchiectasis in Indigenous Australians requires access to comprehensive health care services, as well as improved housing, education and employment and reduced poverty levels. 3) Diagnosis of bronchiectasis requires a chest high-resolution computed tomography scan. Children who have bronchiectasis symptoms but non-diagnostic scans are described as having chronic suppurative lung disease (CSLD), rather than bronchiectasis. Untreated CSLD may progress to bronchiectasis. 4) Chronic wet cough (> 4 weeks) or recurrent wet cough (> 2 episodes/year) are important but often under-reported symptoms. Bronchiectasis is suspected when chronic cough is excessively prolonged (> 12 weeks) or if a chest radiographic abnormality persists despite appropriate therapy. 5) Intensive treatment aims to improve symptom control and quality of life while preserving lung function and reducing acute exacerbation frequency. 6) Antibiotics should be prescribed for acute infective episodes according to culture results of respiratory secretions, local susceptibility patterns and clinical severity. Patients not responding promptly to oral antibiotics should be hospitalised for more intensive treatment. 7) Ongoing care requires regular primary health care and specialist review, including monitoring for complications and comorbidities. Corticosteroids, bronchodilators and mucoactive agents may be used in individual cases, but routine use is not recommended. Physiotherapy and exercise should be encouraged, nutrition optimised, environmental pollutants (including tobacco smoke) avoided, and immunisations maintained.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837683     DOI: 10.5694/j.1326-5377.2008.tb02085.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  14 in total

Review 1.  Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis.

Authors:  Annemarie L Lee; Angela T Burge; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2017-09-27

2.  Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Colin F Robertson; Andrew C Wilson; Peter P van Asperen; Kerry-Ann F O'Grady; Theo P Sloots; Paul J Torzillo; Emily J Bailey; Gabrielle B McCallum; Ian B Masters; Catherine A Byrnes; Mark D Chatfield; Helen M Buntain; Ian M Mackay; Peter S Morris
Journal:  Trials       Date:  2012-08-31       Impact factor: 2.279

3.  Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial.

Authors:  Patricia C Valery; Peter S Morris; Keith Grimwood; Paul J Torzillo; Catherine A Byrnes; I Brent Masters; Paul A Bauert; Gabrielle B McCallum; Charmaine Mobberly; Anne B Chang
Journal:  BMC Pediatr       Date:  2012-08-14       Impact factor: 2.125

Review 4.  Toward making inroads in reducing the disparity of lung health in Australian indigenous and new zealand māori children.

Authors:  Anne B Chang; Robyn L Marsh; John W Upham; Lucas R Hoffman; Heidi Smith-Vaughan; Deborah Holt; Maree Toombs; Catherine Byrnes; Stephanie T Yerkovich; Paul J Torzillo; Kerry-Ann F O'Grady; Keith Grimwood
Journal:  Front Pediatr       Date:  2015-02-13       Impact factor: 3.418

Review 5.  Global impact of bronchiectasis and cystic fibrosis.

Authors:  Margarida Redondo; Holly Keyt; Raja Dhar; James D Chalmers
Journal:  Breathe (Sheff)       Date:  2016-09

Review 6.  The Epidemiology of Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adolescents.

Authors:  Gabrielle B McCallum; Michael J Binks
Journal:  Front Pediatr       Date:  2017-02-20       Impact factor: 3.418

Review 7.  The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis.

Authors:  Kerry-Ann F O'Grady; Keith Grimwood
Journal:  Front Pediatr       Date:  2017-03-24       Impact factor: 3.418

8.  Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis.

Authors:  A B Chang; C A Byrnes; M L Everard
Journal:  Paediatr Respir Rev       Date:  2010-12-04       Impact factor: 2.726

9.  Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Andrew C Wilson; Peter P van Asperen; Catherine A Byrnes; Kerry-Ann F O'Grady; Theo P Sloots; Colin F Robertson; Paul J Torzillo; Gabrielle B McCallum; Ian B Masters; Helen M Buntain; Ian M Mackay; Jacobus Ungerer; Joanne Tuppin; Peter S Morris
Journal:  Trials       Date:  2013-02-20       Impact factor: 2.279

10.  A case of Kartagener syndrome with rhinolalia clausa.

Authors:  Mohammed Raoufi; Hicham Sator; Jawad Lahma; Ali El Ayoubi; Sophia Nitassi; Abdelilah Oujilal; Mohammed Anas Benbouzid; Leila Essakalli; Hanane Elouazzani; Ismail Abderrahmane Rhorfi; Ahmed Abid
Journal:  Pan Afr Med J       Date:  2016-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.